CA2241924A1 - Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts - Google Patents

Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts Download PDF

Info

Publication number
CA2241924A1
CA2241924A1 CA002241924A CA2241924A CA2241924A1 CA 2241924 A1 CA2241924 A1 CA 2241924A1 CA 002241924 A CA002241924 A CA 002241924A CA 2241924 A CA2241924 A CA 2241924A CA 2241924 A1 CA2241924 A1 CA 2241924A1
Authority
CA
Canada
Prior art keywords
tobacco
ages
age
smoke
glycotoxins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002241924A
Other languages
English (en)
French (fr)
Inventor
Anthony Cerami
Richard J. Bucala
Helen Vlassara
Henry W. Founds
Clara J. Cerami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Picower Institute for Medical Research
Synvista Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2241924A1 publication Critical patent/CA2241924A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/36—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/36—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring
    • A24B15/365—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring having nitrogen and sulfur as hetero atoms in the same ring
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES OF CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
    • A24D3/00—Tobacco smoke filters, e.g. filter tips or filtering inserts; Filters specially adapted for simulated smoking devices; Mouthpieces of cigars or cigarettes
    • A24D3/06—Use of materials for tobacco smoke filters
    • A24D3/14—Use of materials for tobacco smoke filters of organic materials as additive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Materials Engineering (AREA)
CA002241924A 1995-12-26 1996-12-23 Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts Abandoned CA2241924A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US921895P 1995-12-26 1995-12-26
US921995P 1995-12-26 1995-12-26
US60/009,218 1995-12-26
US60/009,219 1995-12-26

Publications (1)

Publication Number Publication Date
CA2241924A1 true CA2241924A1 (en) 1997-07-03

Family

ID=26679210

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002241924A Abandoned CA2241924A1 (en) 1995-12-26 1996-12-23 Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts

Country Status (7)

Country Link
EP (1) EP0877943A1 (da)
JP (1) JP2000507346A (da)
CN (1) CN1211321A (da)
AU (1) AU723649B2 (da)
CA (1) CA2241924A1 (da)
IN (1) IN191280B (da)
WO (1) WO1997023783A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5921248A (en) * 1997-03-28 1999-07-13 The Picower Institute For Medical Research Tobacco combination product filter
NZ515049A (en) * 1999-04-15 2004-12-24 Fox Chase Cancer Ct Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
SE0400683D0 (sv) * 2004-03-19 2004-03-19 Forskarpatent I Syd Ab Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis
CN106353434B (zh) * 2016-10-21 2018-10-09 中国烟草总公司郑州烟草研究院 一种定量测定烟草中Amadori化合物的分析方法
CN106769349B (zh) * 2017-01-06 2020-01-21 上海君联医疗设备有限公司 血液中异常糖基化蛋白细胞的检测方法
CN107202843B (zh) * 2017-06-07 2019-08-30 贵州省烟草科学研究院 LC-MS/MS法同时测定烟草中游离氨基酸和Amadori化合物的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US4665192A (en) * 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US4827949A (en) * 1987-09-16 1989-05-09 Sunas Ernest C Method of treating tobacco and tobacco produced thereby
CA1332572C (en) * 1988-01-29 1994-10-18 Anthony Cerami Method and agents for preventing staining of teeth
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
EP1327887A3 (en) * 1995-01-18 2008-12-10 Synvista Therapeutics, Inc. Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation end products

Also Published As

Publication number Publication date
CN1211321A (zh) 1999-03-17
WO1997023783A1 (en) 1997-07-03
JP2000507346A (ja) 2000-06-13
AU1345997A (en) 1997-07-17
IN191280B (da) 2003-10-25
AU723649B2 (en) 2000-08-31
EP0877943A1 (en) 1998-11-18

Similar Documents

Publication Publication Date Title
Thielen et al. Tobacco smoke: unraveling a controversial subject
Djordjevic et al. Self-regulation of smoking intensity. Smoke yields of the low-nicotine, low-‘tar’cigarettes
Nicholl et al. Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers
Bachi et al. Measurement of urinary 8-epi-prostaglandin F2α, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction/gas chromatography-mass spectrometry. Basal levels in smokers and nonsmokers
Foiles et al. Mass spectrometric analysis of tobacco-specific nitrosamine-DNA adducts in smokers and nonsmokers
Morrow et al. The isoprostanes: current knowledge and directions for future research
US6110968A (en) Methods for treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
US5850840A (en) Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
Tricker Biomarkers derived from nicotine and its metabolites: a review
Malaveille et al. Levels of mutagens in the urine of smokers of black and blond tobacco correlate with their risk of bladder cancer
St. Charles et al. A comparison of nicotine dose estimates in smokers between filter analysis, salivary cotinine, and urinary excretion of nicotine metabolites
AU723649B2 (en) Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
Robinson et al. The role of carbon monoxide in cigarette smoking: I carbon monoxide yield from cigarettes
Bogden et al. Composition of tobaccos from countries with high and low incidences of lung cancer. I. Selenium, polonium-210, Alternaria, tar, and nicotine
WO1997023783A9 (en) Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
Scherer et al. Intake and uptake of chemicals upon use of various tobacco/nicotine products: can users be differentiated by single or combinations of biomarkers?
Kraal et al. The response of polymorphonuclear leukocytes to chemotictic stimulation for smokers and non‐smokers
US5854000A (en) Methods for measurement predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
Morin et al. Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure
Harris Smoke yields of tobacco-specific nitrosamines in relation to FTC tar level and cigarette manufacturer: analysis of the Massachusetts Benchmark Study
AU4252700A (en) Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
Behera et al. Serum surfactant protein-A levels in chronic bronchitis and its relation to smoking
MXPA98005261A (en) Methods to measure and treat the pre-calculated calculation on the presence of final products of advanced glicosilation in tobacco and in its combust subproducts
Ding et al. Development of a method to estimate mouth-level benzo [a] pyrene intake by filter analysis
Doolittle et al. The effect of exposure to nicotine, carbon monoxide, cigarette smoke or cigarette smoke condensate on the mutagenicity of rat urine

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead